Does Christiana Care Health System Cover Forteo?

What Is Forteo and Why Does Coverage Matter?

Forteo is an anabolic osteoporosis therapy, not a simple vitamin supplement, and its $3,000 monthly price tag makes insurance authorization the single biggest barrier most Christiana Care patients face. Teriparatide works by mimicking the N-terminal 34 amino acids of endogenous parathyroid hormone, stimulating new bone formation rather than merely slowing resorption the way bisphosphonates do. That biological distinction is clinically significant because the FDA-approved label carries a lifetime maximum of 24 months of use, so every month a prior-authorization delay burns is a month that cannot be recovered. [1]

The foundational trial, published in the New England Journal of Medicine in 2001 (N=1,637 postmenopausal women), showed teriparatide 20 mcg/day reduced new vertebral fractures by 65% versus placebo (relative risk 0.35; 95% CI 0.22 to 0.55; P<0.001) and nonvertebral fragility fractures by 53% at a median of 21 months. [2] Those numbers explain why most clinical guidelines, including the American Association of Clinical Endocrinology 2020 postmenopausal osteoporosis guidelines, recommend anabolic therapy as first-line in patients with very high fracture risk. [3]

Lumbar spine bone mineral density increased by 9.7% from baseline in the teriparatide group at 21 months versus 2.8% in the placebo group in that same trial. [2] For patients with a T-score below -3.0 or a recent hip fracture, that magnitude of gain is difficult to replicate with any oral bisphosphonate.

How Christiana Care Health System Structures Prescription Drug Coverage

ChristianaCare (formerly Christiana Care Health System) offers employees and plan members coverage through several insurance arrangements, including self-insured employer plans administered by major pharmacy benefit managers, Delaware Medicaid managed-care organizations, and Medicare Advantage plans available to eligible retirees. Each of those coverage vehicles has its own formulary tier and prior-authorization protocol for specialty drugs like Forteo. [4]

Specialty drugs at ChristianaCare are generally dispensed through designated specialty pharmacies rather than retail counters. That routing matters because the specialty pharmacy handles the prior-authorization paperwork with the prescribing physician's office, collects clinical documentation (DXA scan results, fracture history, prior medication trials), and submits the case to the plan's medical-policy reviewers. Patients who understand this workflow tend to see shorter approval timelines.

For commercial plans managed by ChristianaCare's affiliated network, Forteo typically lands on the highest specialty tier, meaning the member pays a percentage of the drug's cost (often 20% to 33% coinsurance) rather than a flat copay, unless a patient-assistance program bridges the gap. [5] Medicare Part D plans follow CMS formulary rules, and teriparatide's placement varies by plan year; the CMS online formulary finder at Medicare.gov is the fastest way to confirm the current tier assignment for a specific plan.

Published Medicare Part D data show that specialty-tier drugs like teriparatide commonly trigger catastrophic-phase spending thresholds for beneficiaries over age 65, a group that represents a substantial share of osteoporosis patients. [6] The Inflation Reduction Act of 2022 caps Medicare Part D out-of-pocket costs at $2,000 starting in 2025, which meaningfully changes the calculus for older ChristianaCare patients.

Prior Authorization Criteria Forteo Patients Must Meet

Prior authorization for teriparatide at most U.S. health plans, including those serving ChristianaCare patients, follows clinical-policy criteria that mirror the AACE 2020 guidelines and the National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation) 2022 Clinician's Guide. Plans generally require at least one of the following. [3][7]

A DXA-measured T-score of -2.5 or lower at the lumbar spine or hip combined with a documented fragility fracture (vertebral, hip, wrist, or proximal humerus). A T-score of -3.0 or lower at any site without a fracture requirement in many formularies. Documented failure of, or intolerance to, at least one oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly for a minimum of 12 months) in cases where the T-score is between -2.5 and -3.0. Glucocorticoid-induced osteoporosis with ongoing prednisone use at 7.5 mg/day or higher for three months or longer, per the 2017 ACR glucocorticoid-induced osteoporosis guidelines. [8]

The prescribing clinician at ChristianaCare must submit the DXA report with numeric T-scores, a fracture history, and a list of prior osteoporosis medications tried. Missing even one of those documents is the most common reason for initial denial. Ordering a new DXA before the prior-auth submission, if the existing scan is more than 24 months old, removes that obstacle at the start rather than the appeal stage.

The National Osteoporosis Foundation's 2022 Clinician's Guide states directly: "Treatment should be initiated in postmenopausal women and men aged 50 years or older who present with hip or vertebral fracture, or who have a T-score of -2.5 or below at the femoral neck, total hip, or lumbar spine." [7] That language is frequently reproduced verbatim in commercial insurance medical-policy documents as the justification threshold.

Step-by-Step: Getting Forteo Covered at ChristianaCare

Step 1 is a bone-density DXA scan read and documented by a radiologist with numeric T-scores at the lumbar spine (L1 through L4) and total hip. ChristianaCare's imaging centers perform this scan; it takes roughly 10 to 20 minutes and uses minimal radiation (approximately 1 to 6 microsieverts, comparable to a day of background exposure). [9]

Step 2 is the prescribing visit with an endocrinologist, rheumatologist, or primary-care physician at ChristianaCare who documents the indication, fracture history, prior medication trials, and Forteo's medical necessity in the electronic health record.

Step 3 is the specialty-pharmacy routing. The prescriber sends the Forteo prescription, the prior-authorization form, and clinical notes to the designated specialty pharmacy. Most ChristianaCare-affiliated plans contract with either CVS Specialty, Accredo, or an in-network hospital pharmacy. The specialty pharmacy then contacts the payer's medical-policy team.

Step 4 is waiting for the coverage decision, which typically takes 3 to 14 business days for a standard review or 72 hours for an expedited urgent review if the prescriber documents clinical urgency. [10] Federal law under the Employee Retirement Income Security Act (ERISA) requires most employer-sponsored plans to respond to urgent care requests within 72 hours.

Step 5, if denied, is the appeal. The prescriber submits a peer-to-peer review request with the plan's medical director. Data from the Kaiser Family Foundation analysis of ACA marketplace appeals show that nearly 40% of denied claims are overturned on internal appeal when the provider submits additional clinical documentation. [11] A written letter from the treating physician citing the AACE 2020 guidelines and the NEJM 2001 fracture-reduction data is more persuasive than the standard form appeal alone.

Cost-Assistance Options When Coverage Falls Short

Eli Lilly (Forteo's manufacturer) runs a patient-assistance program called the Lilly Cares Foundation, which provides Forteo at no cost to uninsured or underinsured patients whose household income is at or below 400% of the federal poverty level (approximately $60,240 for a single individual in 2024). [12] The application requires income documentation and a prescriber signature and takes roughly two to four weeks to process.

For insured patients with high cost-sharing, Lilly's Forteo Savings Card has historically reduced out-of-pocket costs to as low as $25 per month for commercially insured patients who are not enrolled in a federal or state government program. Medicare and Medicaid patients are not eligible for manufacturer copay cards under federal anti-kickback rules, but they may qualify for the Lilly Cares Foundation program instead.

Delaware's Pharmaceutical Assistance Program (DPAP) provides additional cost relief for Delaware residents aged 65 and older with annual income below $23,500 (single) or $31,500 (married). [13] ChristianaCare's social work and care-coordination team can assist patients with DPAP enrollment paperwork during or after the prescribing appointment.

For patients switching from Forteo to a less expensive alternative, the biosimilar teriparatide product Bonsity (Alveo) received FDA approval in 2023 and may carry a lower list price on some formularies; clinical bioequivalence data submitted to the FDA confirm it delivers the same 20 mcg/day teriparatide dose. [14] Some ChristianaCare-affiliated plans may require a biosimilar step before approving the branded originator product.

What Happens After Forteo Approval: Clinical Monitoring

Once coverage is confirmed and the first 28-day supply arrives via specialty pharmacy, the patient begins daily subcutaneous injections using the pre-filled Forteo pen (available in a 2.4 mL cartridge delivering 28 doses at 20 mcg each). The injection site rotates between the thigh and abdomen. [1]

The most common adverse effects in the first few doses are dizziness and leg cramps, both attributable to transient hypercalcemia lasting roughly four to six hours post-injection. Lilly's prescribing information recommends that patients sit or lie down when administering their first several doses. Serum calcium should be checked at baseline and again at one to three months into therapy per standard clinical practice. [1]

DXA scanning every 12 months during treatment tracks treatment response. A lumbar spine BMD gain of at least 3% at 12 months is generally considered evidence of a meaningful anabolic response, consistent with the 9.7% gain seen in the NEJM 2001 trial at 21 months. [2] Patients who do not show measurable BMD gain should have adherence reviewed and secondary causes of osteoporosis (vitamin D deficiency, hyperparathyroidism, celiac disease) excluded before assuming drug failure.

The 24-month cumulative lifetime limit is strict. After completing a teriparatide course, nearly all osteoporosis guidelines recommend immediate transition to antiresorptive therapy (alendronate, zoledronic acid, or denosumab) to preserve the bone accrued. The NEJM 2019 Arch trial (N=243) showed that transitioning from teriparatide to zoledronic acid 5 mg IV annually maintained BMD gains better than no follow-on therapy, with total hip BMD 2.4% higher in the zoledronate group versus untreated controls at 24 months post-teriparatide. [15]

Osteoporosis Risk Assessment: Are You a Candidate?

Not every patient with low bone density qualifies for teriparatide under insurance criteria, and prescribers at ChristianaCare use standardized tools to stratify fracture risk before requesting prior authorization. [3]

The FRAX tool (Fracture Risk Assessment Tool), developed by the World Health Organization, calculates a 10-year probability of major osteoporotic fracture using 12 clinical variables including age, sex, body mass index, prior fracture, parental hip fracture, smoking, glucocorticoid use, rheumatoid arthritis, and femoral neck T-score. [16] AACE and the Bone Health and Osteoporosis Foundation recommend initiating pharmacologic therapy when FRAX-calculated 10-year hip fracture probability exceeds 3% or major osteoporotic fracture probability exceeds 20%. [3][7]

Vitamin D deficiency is present in approximately 41.6% of U.S. adults according to data published in Nutrition Research (2011, N=4,495 NHANES participants) [17], and it blunts the response to any osteoporosis medication. ChristianaCare providers routinely order 25-hydroxyvitamin D levels before starting Forteo; a target level of 30 to 50 ng/mL (75 to 125 nmol/L) is recommended by the Endocrine Society's 2011 vitamin D practice guidelines before initiating anabolic therapy. [18]

Patients with a prior history of skeletal malignancy, Paget's disease of bone, unexplained elevations of alkaline phosphatase, or prior radiation to the skeleton are not candidates for teriparatide per the FDA label, due to an observed osteosarcoma signal in a rat toxicology study conducted at supratherapeutic doses. [1] The FDA removed the black-box osteosarcoma warning from the teriparatide label in January 2020 after reviewing 17 years of post-marketing surveillance data showing no confirmed causal link in humans. [19]

Alternatives to Forteo Covered at ChristianaCare

When Forteo authorization is denied or cost remains prohibitive, ChristianaCare prescribers have several evidence-based alternatives supported by major insurance formularies. [3][7]

Alendronate (Fosamax) 70 mg orally once weekly is generic, costs under $15 per month at most pharmacies, and reduced vertebral fracture risk by 47% versus placebo in the FIT trial (N=2,027; 3-year data) published in The Lancet in 1996. [20] Most plans cover it without prior authorization. Risedronate (Actonel) 35 mg weekly offers similar data from the VERT trials. [21]

Denosumab (Prolia) 60 mg subcutaneously every 6 months is a RANK-L inhibitor that reduced new vertebral fractures by 68% and hip fractures by 40% versus placebo in the FREEDOM trial (N=7,808; 36 months) published in the New England Journal of Medicine in 2009. [22] It requires prior authorization at most plans but is generally approved without a bisphosphonate trial requirement in patients with severe osteoporosis.

Zoledronic acid (Reclast) 5 mg IV once yearly reduced hip fractures by 41% versus placebo in HORIZON-PFT (N=7,736; 3 years) published in the New England Journal of Medicine in 2007. [23] Patients who cannot tolerate oral bisphosphonates because of gastrointestinal side effects often qualify for zoledronic acid without additional step-therapy requirements.

Romosozumab (Evenity) 210 mg subcutaneously monthly for 12 months is a second anabolic agent approved by the FDA in April 2019. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced new vertebral fractures by 48% compared with alendronate alone at 24 months (P<0.001). [24] It carries a black-box warning for cardiovascular events and is contraindicated in patients with a prior myocardial infarction or stroke within the preceding year.

Navigating an Appeal or Coverage Denial

A first denial from a ChristianaCare-affiliated plan is not a final answer. The appeals process under ERISA, the ACA, and Delaware insurance regulations gives patients multiple review levels. [10]

The internal appeal must be filed within 180 days of the denial notice for most employer-sponsored plans. The prescriber's appeal letter should cite: (1) the patient's specific T-score and fracture history, (2) the AACE 2020 guideline recommendation language, (3) the 65% vertebral fracture reduction from the NEJM 2001 trial, and (4) why standard bisphosphonate therapy is medically inappropriate or has been tried and failed. Attaching peer-reviewed references as appendices increases credibility during peer-to-peer review calls.

If the internal appeal fails, an external review by an independent review organization (IRO) is available under ACA rules for non-grandfathered plans. External reviewers overturn internal denial decisions in approximately 39% to 62% of cases depending on the clinical category, according to data compiled by the Kaiser Family Foundation. [11] Delaware's Insurance Commissioner also maintains a consumer complaint line (1-800-282-8611) for patients whose insurer fails to follow required timelines.

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation) maintains a free advocacy and resource hotline at 1-800-231-4222 that can provide patients with template appeal letters and local patient advocates.